Payment overview · 2025
General Payments
$46.98
3 reported records · 3 companies
Healthcare provider profile · identity verified
Michael E Burkley, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · WEST BRANCH, MI · NPI 1205823861
Verified facts
What the public records show
CMS Open Payments records show Michael E Burkley, D.O. received $46.98 in general payments during 2025 across 3 reported records.
GlaxoSmithKline, LLC. accounted for 38.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.83 | 38.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.68 | 33.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.47 | 28.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $46.98 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.83 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.47 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
91 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 319 | 78 |
| Amlodipine Besylate | Amlodipine Besylate | 277 | 74 |
| Pantoprazole Sodium | Pantoprazole Sodium | 264 | 50 |
| Levothyroxine Sodium | Levothyroxine Sodium | 250 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 226 | 52 |
| Lisinopril | Lisinopril | 220 | 44 |
| Losartan Potassium | Losartan Potassium | 195 | 41 |
| Omeprazole | Omeprazole | 165 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 161 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 155 | 44 |
| Gabapentin | Gabapentin | 145 | 31 |
| Metformin Hcl | Metformin Hcl | 128 | 24 |
| Potassium Chloride | Potassium Chloride | 126 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 122 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 116 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 111 | 22 |
| Simvastatin | Simvastatin | 110 | 26 |
| Metformin Hcl Er | Metformin Hcl | 101 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 100 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 98 | 24 |
| Telmisartan | Telmisartan | 98 | 22 |
| Furosemide | Furosemide | 97 | 23 |
| Eliquis | Apixaban | 92 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 91 | 19 |
| Ramipril | Ramipril | 90 | 25 |
| Jardiance | Empagliflozin | 88 | 16 |
| Trazodone Hcl | Trazodone Hcl | 84 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 77 | 33 |
| Pioglitazone Hcl | Pioglitazone Hcl | 71 | 14 |
| Chlorthalidone | Chlorthalidone | 69 | 16 |
| Ozempic | Semaglutide | 67 | 12 |
| Sertraline Hcl | Sertraline Hcl | 66 | 12 |
| Levetiracetam | Levetiracetam | 62 | suppressed |
| Pregabalin | Pregabalin | 62 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 59 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 59 | 17 |
| Famotidine | Famotidine | 57 | 12 |
| Allopurinol | Allopurinol | 53 | 14 |
| Montelukast Sodium | Montelukast Sodium | 53 | 16 |
| Januvia | Sitagliptin Phosphate | 51 | suppressed |
| Finasteride | Finasteride | 49 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 48 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 47 | 12 |
| Alendronate Sodium | Alendronate Sodium | 42 | 11 |
| Trulicity | Dulaglutide | 42 | suppressed |
| Lorazepam | Lorazepam | 41 | suppressed |
| Spironolactone | Spironolactone | 40 | suppressed |
| Alprazolam | Alprazolam | 38 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Mirtazapine | Mirtazapine | 36 | suppressed |
| Ezetimibe | Ezetimibe | 35 | suppressed |
| Clonazepam | Clonazepam | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 33 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Naproxen | Naproxen | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Nystatin | Nystatin | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | suppressed |
| Invokana | Canagliflozin | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 23 | suppressed |
| Carvedilol | Carvedilol | 22 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 22 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Meloxicam | Meloxicam | 19 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 18 | suppressed |
| Trimethoprim | Trimethoprim | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Prednisone | Prednisone | 15 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $46.98 · 3 records | GlaxoSmithKline, LLC. | OTEZLA, REPATHA, SHINGRIX, Veozah | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error